Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28904654 | 0.94 | — | — | |
| SCHEMBL150150 | 0.87 | — | — | |
| SCHEMBL29952085 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL28476289 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL28900523 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL11985665 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL28475484 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL1854104 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL28900538 | 0.85 | HDAC4 (0.34) | — | |
| SCHEMBL15849818 | 0.85 | HDAC4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204308-A1 | OXAZEPINE DERIVATIVE | 帝人ファーマ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| US-20230303543-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-4190401-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | National University Corporation Okayama University (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-106831845-B | Boron-containing organosilicon compounds, method for the production and use thereof | 北京康美特科技股份有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | ALDH1A1 467/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | ALDH1A1 554/4885 |
| US-20230303543-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | LDHA, SDHA, LDHB | ALDH1A1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.